文献速递咽喉与嗓音头颈外科

术前SGLT2抑制剂与2型糖尿病患者气管造口术后并发症

Preoperative SGLT2 Inhibitors and Postoperative Complications After Tracheostomy in Type 2 Diabetes.
PubMed 文献 · Laryngoscope · 2026-01-18

本研究为多机构电子健康记录回顾性队列研究,纳入2013至2024年接受开放手术气管造口的2型糖尿病成人,比较术前180天内使用SGLT2抑制剂者与未使用者术后90天和180天并发症。倾向评分匹配后每组1327例,SGLT2i使用与90天心力衰竭加重(OR 1.70)及180天低血糖(OR 2.01)和心力衰竭加重(OR 1.61)风险升高相关。

要点

  • 术前使用SGLT2i与气管造口术后90天心力衰竭加重风险升高相关。
  • 180天时SGLT2i使用与低血糖和心力衰竭加重风险升高相关。
  • 手术部位感染、造口故障及头晕/眩晕信号经校正后不显著。

核心结论

  • 在2型糖尿病接受开放手术气管造口的成人中,术前SGLT2i使用与术后低血糖和心力衰竭加重风险升高相关。

研究设计与样本

  • 多机构电子健康记录网络回顾性队列研究,纳入2013至2024年接受开放手术气管造口的2型糖尿病成人。
  • 共36840例符合条件成人(SGLT2i组1329例,非SGLT2i组35511例),经1:1倾向评分匹配后每组1327例。

主要发现

  • 90天时SGLT2i使用与心力衰竭加重风险升高相关(OR 1.70,95%CI 1.36-2.14),经FDR校正后仍显著。
  • 180天时SGLT2i使用与低血糖(OR 2.01,95%CI 1.30-3.13)和心力衰竭加重(OR 1.61,95%CI 1.30-1.99)风险升高相关,经FDR校正后均显著。
  • 手术部位感染、气管造口故障和头晕/眩晕的信号经校正后不显著。

临床怎么用

  • 对接受开放手术气管造口的2型糖尿病高危患者,应加强围手术期SGLT2i管理。
  • 需开展前瞻性研究以确定最佳的SGLT2i停药策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether preoperative sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is associated with postoperative complications in adults with type 2 diabetes mellitus (T2DM) undergoing open surgical tracheostomy (OST) METHODS: We performed a retrospective cohort study using a multi-institutional electronic health record network. Adults with T2DM who underwent OST between 2013 and 2024 were identified using CPT and ICD-10-PCS codes. Exposure was defined as an SGLT2i prescription within 180 days before surgery. One-to-one propensity score matching on demographics, comorbidities, preoperative ventilator dependence, medications, and laboratory values generated balanced SGLT2i and non-SGLT2i cohorts. Ninety- and 180-day postoperative complications were compared using odds ratios (ORs) with 95% confidence intervals, with Benjamini-Hochberg false discovery rate (FDR) correction. RESULTS: Of 36,840 eligible adults (1329 SGLT2i; 35,511 non-SGLT2i), 1327 patients remained in each cohort after matching. At 90 days, SGLT2i use was associated with higher odds of heart failure exacerbation (OR 1.70, 95% CI 1.36-2.14), which remained significant after FDR adjustment. At 180 days, SGLT2i use was associated with increased odds of hypoglycemia (OR 2.01, 95% CI 1.30-3.13) and heart failure exacerbation (OR 1.61, 95% CI 1.30-1.99), both significant after FDR correction. Signals for surgical site infection, tracheostomy stoma malfunction, and dizziness/vertigo did not remain significant after adjustment. CONCLUSION: In adults with T2DM undergoing OST, preoperative SGLT2i use was associated with increased postoperative hypoglycemia and heart failure exacerbation. These findings support careful perioperative management of SGLT2is in high-risk airway surgery and justify prospective studies to define optimal discontinuation strategies.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Singh S, Matharu SS, Choudhury A, et al. Preoperative SGLT2 Inhibitors and Postoperative Complications After Tracheostomy in Type 2 Diabetes. Laryngoscope. 2026. PMID: 41549538. doi:10.1002/lary.70374

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。